Abstract
We conducted a nationwide retrospective cohort study to estimate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection among recipients of 4 different vaccines in South Korea. Age-adjusted breakthrough infection rate per month was highest for Janssen (42.6/100,000 population), followed by AstraZeneca (21.7/100,000 population), Pfizer-BioNTech (8.5/100,000 population), and Moderna (1.8/100,000 population).
Cite
CITATION STYLE
Yi, S., Choe, Y. J., Kim, J., Kim, Y. Y., Kim, R. K., Jang, E. J., … Park, Y. J. (2022). SARS-CoV-2 Breakthrough Infections after Introduction of 4 COVID-19 Vaccines, South Korea, 2021. Emerging Infectious Diseases, 28(3), 753–756. https://doi.org/10.3201/eid2803.212210
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
